Authors : Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L,
Commentary
Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH.
PPARs are nuclear receptors that regulate metabolic homeostasis, cell differentiation and immune-inflammation. Several PPAR intracellular receptor subtypes exert different distribution and actions in different tissues.
PPAR activation has been established to play a role in regulating each of the four components of NASH. Lanifibranor is the only product candidate in clinical development targeting all three PPAR isoforms. This pan-PPAR approach provides for a combination of anti-fibrotic, anti-inflammatory and beneficial metabolic effects that cannot be obtained with single and dual PPAR agonists.
